Amylin: The Satiety Hormone Doctors Don't Discuss

Cagrilintide (cagrilintide, trade name Amilin) — a long-acting analog of human amylin hormone from Novo Nordisk. Amylin is a hormone from pancreatic β-cells that acts through a different pathway than GLP-1: area postrema and nucleus tractus solitarius in the brain. In monotherapy, cagrilintide showed -10.8% weight loss (JAMA 2021), and in combination with semaglutide (CagriSema) — -22.7% over 68 weeks (REDEFINE 2, Lancet 2024), which is comparable to Mounjaro (-22.5%). Available through DOZA under the name Amilin 20 mg from PeptoLabs.

What if I told you there's a satiety hormone that works completely differently than popular Ozempic or Mounjaro? A hormone that your body produces naturally after every meal. A hormone that most people have never heard of. Meet amylin.

What is Amylin? The Hormone They Don't Tell You About

Amylin is a peptide hormone discovered over three decades ago in patients with type 2 diabetes [5]. It consists of 37 amino acids and is produced by pancreatic β-cells. Every time you eat, amylin is released along with insulin in response to rising glucose levels [5].

Why is so little said about it? Because natural amylin has a critical flaw. It works for only a few minutes before being rapidly degraded in the body. That's why pharmaceutical companies spent decades searching for a way to create a long-acting analog.

Amylin's main function is signaling the brain "stop eating." But it doesn't do this like GLP-1 drugs. Amylin reduces post-meal glucagon levels, slows gastric emptying, and centrally suppresses appetite—through specific brain regions [6].

Amylin receptors (AMY1, AMY2, AMY3) are heterodimers formed by the calcitonin receptor combined with modifying RAMP proteins [4]. They're located primarily in the posterior brain. And this anatomical feature makes amylin a unique player in weight control.

Pramlintide (Symlin) became the first synthetic amylin analog approved for diabetes control. It showed weight reduction up to 7.9% [28]. But it required daily injections. This changed with the advent of cagrilintide.

Cagrilintide - Long-Acting Amylin Analog from Novo Nordisk

Cagrilintide is the first long-acting amylin analog that requires only one subcutaneous injection per week [7]. Developed by Novo Nordisk — the same company that created Ozempic and Wegovy.

How does it differ from natural amylin? Primarily in duration of action. Natural amylin works for minutes, while cagrilintide works for 7 days [2]. This became possible through molecular structure modifications that slow drug degradation in the body.

In Ukraine, cagrilintide is available under the trade name Amilin from PeptoLabs — in a 20 mg vial designed for complete titration and maintenance therapy over several months.

In phase 2 clinical trials, cagrilintide at doses from 0.3 to 4.5 mg significantly reduced body weight—from 6.0% to 10.8% over 26 weeks [7]. This was a placebo-adjusted reduction of 3.0% to 7.8% (P<0.001). Importantly—the 4.5 mg dose exceeded liraglutide 3.0 mg results: 10.8% vs 9.0% [20].

Most common side effects are gastrointestinal disorders and injection site reactions [7]. We'll discuss these in detail below.

Application is simple: subcutaneous injection once weekly in abdomen, thigh, or upper arm [2]. No tablet form of cagrilintide exists or is planned for development. Injectable route ensures stable drug concentration in blood throughout the week.

Amylin vs GLP-1 - Two Completely Different Appetite Control Pathways

Here's where it gets most interesting. Cagrilintide suppresses appetite by acting on the area postrema and nucleus tractus solitarius in the brainstem [4]. These are completely different anatomical points from where GLP-1 drugs act.

Area postrema is a circumventricular organ in the hindbrain, located outside the blood-brain barrier [5]. It contains neurons directly activated by peripheral amylin. The signal spreads to the adjacent nucleus of the solitary tract (NTS), lateral parabrachial nucleus (LPBN), and central nucleus of the amygdala [24].

Key point: amylin and GLP-1 act on different receptors. Therefore they can be combined for synergistic effect [4]. This isn't simple addition. It's true synergy, where the combination effect exceeds the sum of individual components.

CagriSema achieves appetite suppression through brainstem-mediated satiety signaling [4]. The amylin component acts on area postrema and NTS—regions that process peripheral satiety signals and regulate meal termination. This complements hypothalamic appetite suppression by semaglutide.

Additional mechanistic advantage—dual gastric emptying delay [4]. Amylin slows it through brain pathways, while GLP-1 does so through vagal and direct smooth muscle mechanisms. Amylin also acts on both homeostatic and hedonic brain zones, potentially reducing reward-driven eating beyond simple caloric regulation.

Amylin for Weight Loss - Clinical Trial Results

Now for specific numbers. How much can you actually lose?

The phase 2 study (Lau et al., 2021) included 706 people with overweight or obesity [12]. Participants received various cagrilintide doses—from 0.3 to 4.5 mg weekly—for 26 weeks.

Results by dose:

• 0.3 mg/week: approximately -4% body weight [3]
• 0.6 mg/week: approximately -6% body weight [3]
• 1.2 mg/week: intermediate results
• 2.4 mg/week: -10% over 26 weeks [7]
• 4.5 mg/week: -10.8% over 26 weeks [12]

Interestingly, at 32 weeks (6 weeks after treatment discontinuation), mean weight loss with cagrilintide 0.3-4.5 mg ranged from -5.0% to -9.8% [12]. Compare to -6.1% to -10.8% at 26 weeks. This indicates some effect preservation even after course completion.

The number of participants achieving categorical weight loss of at least 5%, 10%, and 15% at 26 weeks is shown in the publication [12]. Waist circumference reduction with cagrilintide 1.2-4.5 mg was dose-dependent, greater than placebo, and similar to liraglutide 3.0 mg.

But here's what's important to understand. Monotherapy is only part of the picture. The real breakthrough came when cagrilintide was combined with semaglutide.

CagriSema - The Future of Combination Therapy

CagriSema is a fixed combination of two peptide drugs: semaglutide 2.4 mg (GLP-1 receptor agonist) and cagrilintide 2.4 mg (long-acting amylin analog) [15]. Administered together as one subcutaneous injection weekly using a dual-chamber device.

The logic is simple: semaglutide and cagrilintide suppress appetite through different receptor systems. And the combination provides greater weight loss than either drug alone [15].

REDEFINE 1 study results (n=3417 participants) [1]:

• CagriSema: -22.7% weight loss
• 60% of participants achieved ≥20% weight loss
• 23% of participants achieved ≥30% weight loss

For comparison, in the same study [1]:

• Semaglutide 2.4 mg alone: -16.1%
• Cagrilintide 2.4 mg alone: -11.8%
• Placebo: -2.3%

Note: CagriSema (22.7%) exceeded the sum of individual component effects. Semaglutide gave 16.1%, cagrilintide gave 11.8%. If this were simple addition, we'd expect around 15-18% (since effects partially overlap). But we got 22.7%. This proves true synergy [1].

Currently CagriSema is available only through clinical trial participation (REDEFINE program) [1]. But there's already the possibility of combining individual components under specialist supervision.

Cagrilintide + Mounjaro - Can They Be Combined?

Theoretically amylin + tirzepatide = three appetite control pathways (GLP-1, GIP, amylin). This sounds attractive. But there's an important caveat.

No clinical data available for the combination of cagrilintide + Mounjaro. No randomized controlled studies have tested this combination.

Theoretical protocol (clinically unstudied) [3]:

• Stabilization on tirzepatide 10-15 mg for 4+ weeks
• Continue tirzepatide at current dose
• Add cagrilintide 0.6 mg/week
• Standard cagrilintide titration to 2.4 mg

If considering such combination, it's possible only off-label under specialist supervision. CagriSema already has data, so it's the evidence-based combination therapy option with amylin.

In Ukraine, through the DOZA service, you can get an individual consultation about cagrilintide (Amilin) and assess whether it's suitable as an addition to current therapy.

Cagrilintide Dosing - How to Use Amylin 20 mg

Since cagrilintide is still in research stages, official prescribing recommendations don't yet exist [2]. What we know about dosing comes from clinical trials.

Standard cagrilintide titration—12-week period from 0.6 mg to 2.4 mg weekly [3]:

Conservative approaches extend titration to 16-20 weeks for better tolerance of gastrointestinal side effects [3]. This is especially relevant for people sensitive to nausea.

Clinical trials tested a range from 0.3 mg to 4.5 mg weekly [2]. Medium and higher doses (around 2.4-4.5 mg/week) showed the most promising weight loss results.

Amilin from PeptoLabs — is a 20 mg vial. Administration: 1 subcutaneous injection per week. Insulin syringes are used for precise dosing. Injection site: abdomen or thigh [13]. DOZA specialists select individual doses depending on body response.

Storage conditions: cold chain 2–8°C.

Cagrilintide Side Effects

Honestly about side effects—this is important for making an informed decision.

Most common adverse events in clinical trials are gastrointestinal disorders and injection site reactions [7].

Specific data from REDEFINE 1 study [1]:

• Nausea: ~32% with CagriSema, ~33% with cagrilintide alone
• Most events occurred during dose escalation phase

Gastrointestinal disorders (nausea, vomiting, diarrhea) are the "price" of effectiveness. They're related to the drug's mechanism of action. But there's good news.

Injection site reactions occur in approximately 14% of cases. This may be redness, swelling, or itching. Usually temporary and doesn't require discontinuation.

Mean systolic blood pressure changes with CagriSema were -13 mmHg [19]. For comparison: -1 mmHg with semaglutide and -3 mmHg with cagrilintide alone. Mean pulse change: +3, +7, and -1 respectively. No level 2 or 3 hypoglycemia was recorded [19].

Important: side effects are manageable under specialist supervision. Gradual dose titration is key to minimizing discomfort.

Who Is Suitable for Amylin (Cagrilintide)?

Cagrilintide (Amylin) may be an option in four main scenarios:

1. GLP-1 Plateau

Are you taking Ozempic or Mounjaro, achieved certain results, but weight has "stalled"? Adding the amylin pathway can overcome plateaus without increasing GLP-1 doses.

2. GLP-1 Intolerance

Some people cannot tolerate GLP-1 drugs due to severe nausea or other side effects. Cagrilintide acts through a different mechanism and may be an alternative.

3. Combination Therapy

CagriSema showed -22.7% weight loss—on par with tirzepatide [1]. For those seeking maximum effect, amylin + GLP-1 combination may be the optimal choice.

4. Different Control Pathway

Amylin acts on hedonic brain zones, potentially reducing emotional overeating [4]. If your problem is "eating for pleasure," amylin may help specifically with this.

Who is NOT suitable:

• Pregnancy and breastfeeding
• Serious gastrointestinal disorders
• History of medullary thyroid cancer
• Multiple endocrine neoplasia type 2 (MEN-2)

Why are original product prices justified? Each Mounjaro vial is Made in UK by Eli Lilly, certified by MHRA. Add to this individual support from a DOZA specialist — and you get not just a product, but a comprehensive weight loss program.

What to Choose: Amylin Alone or CagriSema?

Summarizing all data, we have this picture:

Cagrilintide (Amylin) mono:

• Weight loss: -6% to -10.8% over 26 weeks [7]
• Suitable as GLP-1 alternative or addition
• Available now through DOZA

CagriSema (cagrilintide + semaglutide):

• Weight loss: -22.7% over 68 weeks [1]
• Most effective evidence-based combination
• FDA approval expected late 2026

Mounjaro (tirzepatide):

• Weight loss: -22.5% over 72 weeks [32]
• Dual GIP/GLP-1 agonist
• Available now through DOZA

Ozempic (semaglutide):

• Weight loss: -14.9% over 68 weeks [46]
• GLP-1 agonist
• Widely available

Conclusion: Is Amylin Worth Your Attention?

Amylin isn't "just another weight loss drug." It's a fundamentally different approach to appetite control. It acts through area postrema and nucleus tractus solitarius—brain zones that GLP-1 drugs barely touch.

CagriSema data confirms the main thesis: combining different pathways gives better results. 22.7% weight loss is comparable to the best Mounjaro offers.

If you're already on GLP-1 and seeking ways to overcome plateaus. If you can't tolerate GLP-1 and need an alternative. Or if you simply want to understand all options before starting a program—cagrilintide is worth your attention.

At DOZA you can get original Amilin (cagrilintide) from PeptoLabs along with specialist consultation — they will help determine which approach suits you best: monotherapy, combination, or another path.

Amylin Available in Two Formats

Original PeptoLabs product is available in two options—depending on whether you're ready to start a full course or first want to try the drug and feel your body's response.

Weight loss isn't a matter of willpower. It's a matter of the right tool.

Where to Order Mounjaro in Ukraine

Ready to start the course? Buy Mounjaro in Ukraine is available in the DOZA catalog — all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) with official thermal delivery within 24 hours and 24/7 specialist support. Current Mounjaro prices 2026 — from 1,000 ₴ for test dose or 8,000 ₴/month for full program with monitoring.

Where to Order DOZA Products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for starter dose.
• Buy Amilin in Ukraine — original Cagrilintide 20 mg from PeptoLabs, amylin hormone analog. Thermobox 2–8°C with temperature sensor, verified serial number, express delivery 1–2 hours in Kyiv/Lviv/Dnipro or Nova Poshta 1–2 days throughout Ukraine. Amilin price 2026 — 16,400 ₴ per pen, free DOZA consultation before purchase.